Stock Overview

West Pharmaceutical Services Inc (WST)

NYSE · Healthcare · Medical Instruments & Supplies

West Pharmaceutical Services Inc is a Healthcare company with a market capitalization of $24.79B, a trailing P/E ratio of 47.0, and a dividend yield of 0.25%.

Market Cap
$24.79B
P/E (TTM)
47.0
Forward P/E
40.8
Price/Sales
7.7
Price/Book
8.3
EV/EBITDA
29.0
Dividend Yield
0.25%
Beta
1.18
EPS (TTM)
$7.47
Profit Margin
16.9%
ROE
19.1%
52W High
$352.31
52W Low
$206.12

5-Year Price History

Latest Annual Financials · FY ending December 31, 2025

Revenue
$3.07B
Gross Profit
$1.10B
Operating Income
$617.40M
Net Income
$493.70M
Free Cash Flow
$468.90M
Total Debt
$225.50M
Cash & Equivalents
$791.30M
Shareholder Equity
$3.18B

Recent Quarterly Earnings (EPS)

QuarterReportedActual EPSEstimateSurprise
Q1 2026April 23, 2026$2.13$1.68+26.8%
Q4 2025February 12, 2026$2.04$1.83+11.5%
Q3 2025October 23, 2025$1.92$1.67+15.0%
Q2 2025July 24, 2025$1.84$1.54+19.5%
Q1 2025April 24, 2025$1.45$1.26+15.1%
Q4 2024February 13, 2025$1.82$1.71+6.4%

Other Medical Instruments & Supplies Stocks

Frequently Asked Questions

What is West Pharmaceutical Services Inc's market cap?

As of June 29, 2026, West Pharmaceutical Services Inc (WST) has a market capitalization of $24.79B.

What is West Pharmaceutical Services Inc's P/E ratio?

West Pharmaceutical Services Inc trades at a trailing price-to-earnings (P/E) ratio of 47.0. Its forward P/E is 40.8.

Does West Pharmaceutical Services Inc pay a dividend?

Yes — West Pharmaceutical Services Inc pays a dividend yielding 0.25%, an annual payout of $0.86 per share.

What sector is WST in?

West Pharmaceutical Services Inc is in the Healthcare sector, specifically the Medical Instruments & Supplies industry.

What was West Pharmaceutical Services Inc's revenue?

In its latest reported fiscal year (ending December 31, 2025), West Pharmaceutical Services Inc reported revenue of $3.07B and net income of $493.70M.

Ask your own questions about WST

Try mrmarket.ai free

Data as of June 29, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.